1. Daboialipase, a phospholipase A 2 from Vipera russelli russelli venom posesses anti-platelet, anti-thrombin and anti-cancer properties.
- Author
-
Kolvekar N, Bhattacharya N, Mondal S, Sarkar A, and Chakrabarty D
- Subjects
- Animals, Humans, Thrombin antagonists & inhibitors, Viper Venoms chemistry, Antineoplastic Agents chemistry, Antineoplastic Agents isolation & purification, Antineoplastic Agents pharmacology, Anticoagulants chemistry, Anticoagulants isolation & purification, Anticoagulants pharmacology, Phospholipases A2 chemistry, Phospholipases A2 isolation & purification, Phospholipases A2 pharmacology, Vipera
- Abstract
Snake venoms are known to contain toxins capable of interfering with normal physiological processes of victims. Specificity of toxins from snake venoms give scope to identify new molecules with therapeutic action and/or help to understand different cellular mechanisms. Russell's viper venom (RVV) is a mixture of many bioactive molecules with enzymatic and non-enzymatic proteins. The present article describes Daboialipase (DLP), an enzymatic phospholipase A
2 with molecular mass of 14.3 kDa isolated from RVV. DLP was obtained after cation exchange chromatography followed by size-exclusion high performance liquid chromatography (SE-HPLC). The isolated DLP presented strong inhibition of adenosine di-phosphate (ADP) and collagen induced platelet aggregation. It also showed anti-thrombin properties by significantly extending thrombin time in human blood samples. Trypan blue and resazurin cell viability assays confirmed time-dependent cytotoxic and cytostatic activities of DLP on MCF7 breast cancer cells, in vitro. DLP caused morphological changes and nuclear damage in MCF7 cells. However, DLP did not cause cytotoxic effects on non-cancer HaCaT cells. Peptide sequences of DLP obtained by O-HRLCMS analysis showed similarity with a previously reported PLA2 (Uniprot ID: PA2B_DABRR/PDB ID: 1VIP_A). An active Asp at 49th position, calcium ion binding site and anticoagulant activity sites were identified in 1 VIP_A. These findings are expected to contribute to designing new anti-platelet, anticoagulant and anti-cancer molecules., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Ltd. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF